Susan Halabi
#110,911
Most Influential Person Now
American bioinformatician
Susan Halabi's AcademicInfluence.com Rankings
Susan Halabibiology Degrees
Biology
#9384
World Rank
#12582
Historical Rank
#2421
USA Rank
Bioinformatics
#108
World Rank
#110
Historical Rank
#19
USA Rank
Download Badge
Biology
Susan Halabi's Degrees
- Bachelors Biology Stanford University
Similar Degrees You Can Earn
Why Is Susan Halabi Influential?
(Suggest an Edit or Addition)According to Wikipedia, Susan Halabi is a professor of biostatistics and bioinformatics at Duke University, known for her research on prostate cancer. As a member of the data safety monitoring board for a study of the anti-prostate cancer effects of abiraterone acetate , she argued that stopping the study early had prevented the study from accurately determining the effectiveness of the drug, and possibly made it appear to be more effective than it actually was. She also took part in a study showing that, when prostate cancer has reached the point of spreading to other parts of the body, the parts that it spreads to can be used to predict the survival rate from the disease.
Susan Halabi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008) (2023)
- A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. (2003) (1150)
- Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. (1999) (1024)
- Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. (1999) (902)
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
- Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. (2010) (759)
- Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. (2008) (687)
- Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. (2003) (675)
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. (2017) (539)
- Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). (2004) (512)
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. (2018) (452)
- Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. (2009) (443)
- Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. (2012) (431)
- American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. (2007) (403)
- Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. (2003) (398)
- Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. (2014) (391)
- Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. (2016) (308)
- Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. (2001) (287)
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer (2010) (284)
- Circulating levels of inflammatory cytokines and risk of colorectal adenomas. (2008) (281)
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. (2016) (281)
- Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. (2001) (272)
- Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. (2017) (262)
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. (2020) (260)
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update (2018) (258)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (2015) (256)
- Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. (2019) (236)
- American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine (2016) (232)
- Potential Adverse Effects of Resveratrol: A Literature Review (2020) (228)
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study (2019) (227)
- Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). (2014) (210)
- Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. (2004) (201)
- Validation of a breast cancer risk assessment model in women with a positive family history. (1994) (182)
- Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. (2008) (179)
- Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium (2021) (178)
- Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. (2012) (169)
- The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480 (2005) (163)
- Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. (2001) (156)
- A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. (2010) (155)
- Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. (2012) (147)
- Cancer and Leukemia Group B 90206 (2004) (147)
- Breast cancer screening behaviors and attitudes in three racial/ethnic groups (1992) (146)
- Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. (2013) (145)
- Effects of a mammography decision-making intervention at 12 and 24 months. (2002) (140)
- The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. (2010) (132)
- Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety (2020) (128)
- Can tailored interventions increase mammography use among HMO women? (2000) (123)
- Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. (2008) (119)
- Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. (1999) (118)
- A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. (2009) (114)
- Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. (1993) (111)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (110)
- Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. (2005) (103)
- Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. (2009) (100)
- Frequent detection of bcl-2/JH translocations in human blood and organ samples by a quantitative polymerase chain reaction assay. (1995) (99)
- Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study (2007) (99)
- The short-term impact of tailored mammography decision-making interventions. (2001) (93)
- Factors associated with repeat mammography screening. (2000) (93)
- Phase II study of high‐dose fish oil capsules for patients with cancer‐related cachexia (2004) (93)
- Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes (2017) (89)
- Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. (2011) (87)
- A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma (2000) (86)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (85)
- Incidence of Autoimmune Disease in Patients after Breast Reconstruction with Silicone Gel Implants Versus Autogenous Tissue: A Preliminary Report (1993) (85)
- Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. (2013) (84)
- The impact of abnormal mammograms on psychosocial outcomes and subsequent screening (2000) (81)
- Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. (2013) (80)
- Factors associated with perceived risk of breast cancer among women attending a screening program (1993) (78)
- Analgesic Drug Use and Risk of Ovarian Cancer (2006) (76)
- Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. (2018) (75)
- A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinoma (2003) (75)
- A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. (1999) (73)
- Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. (2018) (71)
- Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. (2019) (69)
- A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer (2010) (68)
- The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). (2015) (64)
- A phase II study of gemcitabine and capecitabine in metastatic renal cancer (2006) (62)
- Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy (2017) (62)
- Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. (1996) (62)
- Trinucleotide Repeat Polymorphisms in the Androgen Receptor Gene and Risk of Ovarian Cancer (2007) (61)
- Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. (2004) (61)
- Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. (2017) (60)
- A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate‐resistant prostate cancer (2011) (60)
- Age at Natural Menopause and the Risk of Epithelial Ovarian Cancer (2001) (56)
- Women's interest in chemoprevention for breast cancer. (2001) (56)
- A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. (2013) (56)
- A min–max combination of biomarkers to improve diagnostic accuracy (2011) (56)
- Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States) (2002) (55)
- Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. (2021) (55)
- Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. (2010) (54)
- Association between family history of cancer and mutagen sensitivity in upper aerodigestive tract cancer patients. (1993) (54)
- Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. (2008) (54)
- Design issues in randomized phase II/III trials. (2012) (54)
- Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. (2001) (52)
- Inverse correlation between body mass index and clinical outcomes in men with advanced castration–recurrent prostate cancer (2007) (52)
- A phase II trial of cisplatin, fixed dose‐rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102 (2007) (51)
- Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. (2003) (51)
- Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (2021) (49)
- A tailored intervention to aid decision-making about hormone replacement therapy. (2002) (49)
- Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial (2001) (48)
- The importance of identifying and validating prognostic factors in oncology. (2010) (47)
- Serum androgens: associations with prostate cancer risk and hair patterning. (1997) (47)
- Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. (2019) (47)
- Anthropometric Measurements and Epithelial Ovarian Cancer Risk in African–American and White women (2005) (46)
- Identification of women at increased risk for breast cancer in a population-based screening program. (1992) (45)
- Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. (2002) (44)
- Prognostic Factors in Early‐Onset Epithelial Ovarian Cancer: A Population‐Based Study (2000) (43)
- Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. (2006) (43)
- Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy (2016) (42)
- Progression‐free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma (2014) (41)
- Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. (2010) (40)
- Overview of bladder cancer trials in the Cancer and Leukemia Group B (2003) (40)
- Estimating historical atmospheric mercury concentrations from silver mining and their legacies in present-day surface soil in Potosí, Bolivia (2011) (39)
- Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. (2006) (39)
- Reliability and validity of self and proxy reporting of morbidity data: a case study from Beirut, Lebanon. (1992) (39)
- Critical Assessment of Clinical Prognostic Tools in Melanoma (2016) (38)
- Cyclin E Overexpression in Epithelial Ovarian Cancer Characterizes an Etiologic Subgroup (2008) (38)
- Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). (2019) (37)
- Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. (2009) (37)
- Second-line chemotherapy for advanced hormone-refractory prostate cancer. (2008) (35)
- Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. (2022) (35)
- Measures of social class based on education for use in health studies in developing countries. (1987) (34)
- CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma. (2019) (34)
- Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. (2019) (34)
- A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses (2019) (33)
- Menopausal hormones and risk of ovarian cancer. (2005) (32)
- Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance) (2015) (31)
- Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer (2020) (31)
- Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate‐risk prostate cancer (2011) (31)
- Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools (2015) (30)
- The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). (2015) (30)
- Impact of race on survival in men with metastatic hormone-refractory prostate cancer. (2004) (30)
- No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. (2003) (30)
- Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. (2020) (29)
- Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP). (2018) (29)
- Confusion about mammography: prevalence and consequences. (1999) (28)
- Sample size determination for comparing several survival curves with unequal allocations (2004) (28)
- Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. (2005) (27)
- Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study. (2020) (27)
- Predictors of Prostate Cancer Tissue Acquisition by an Undirected Core Bone Marrow Biopsy in Metastatic Castration-Resistant Prostate Cancer—A Cancer and Leukemia Group B Study (2005) (26)
- Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980 (2008) (26)
- Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. (2020) (26)
- Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. (2006) (26)
- The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer (2008) (25)
- Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102. (2006) (25)
- Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance). (2013) (25)
- Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial (2019) (24)
- Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19 (2021) (23)
- Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. (2020) (23)
- Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN). (2015) (23)
- Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer (2021) (22)
- Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. (2015) (21)
- Antidepressant Medication Use for and Risk of Ovarian Cancer (2005) (21)
- Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. (2009) (21)
- The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate‐resistant prostate cancer (2013) (20)
- p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). (2008) (20)
- CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial (2016) (19)
- Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. (2019) (19)
- Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (2020) (19)
- Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer. (2020) (19)
- A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance (2020) (19)
- Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC). (2010) (18)
- Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance) (2021) (18)
- Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. (2021) (18)
- The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. (2007) (18)
- Low incidence of familial breast cancer among Hispanic women (1992) (18)
- Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (2020) (18)
- Recruiting older women for screening mammography. (1993) (18)
- The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E). (2018) (18)
- A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008. (2004) (17)
- HYDROCORTISONE (H) WITH OR WITHOUT MITOXANTRONE (M) IN MEN WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC). THE RESULTS OF CALGB 9182 (1999) (17)
- Residential Mercury Contamination in Adobe Brick Homes in Huancavelica, Peru (2013) (17)
- Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903. (2012) (17)
- Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy (2012) (17)
- Adjusting for misclassification in a stratified biomarker clinical trial (2014) (16)
- Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer (2019) (16)
- Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma (2002) (16)
- Estimations of historical atmospheric mercury concentrations from mercury refining and present-day soil concentrations of total mercury in Huancavelica, Peru. (2012) (16)
- Developing and Validating Risk Assessment Models of Clinical Outcomes in Modern Oncology. (2019) (16)
- The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. (2014) (16)
- Transforming growth factor β receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk (2005) (16)
- The Texas Breast Screening Project: Part II: Demographics, Risk Profiles, and Health Practices of Participants (1993) (15)
- Mercury hair levels and factors that influence exposure for residents of Huancavelica, Peru (2015) (15)
- Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. (2005) (15)
- Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. (2021) (15)
- Independent data monitoring committees: an update and overview. (2015) (14)
- A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance) (2015) (14)
- A randomized trial of aspirin to prevent colorectal adenomas in patients with previous (2003) (14)
- Epirubicin and ifosfamide in metastatic breast cancer. (1996) (14)
- A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer (2021) (14)
- The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. (2019) (14)
- Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. (2008) (13)
- A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy (2015) (13)
- Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. (2008) (13)
- Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable‐risk localized prostate cancer (2008) (12)
- Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. (2021) (12)
- Phase II trial of the PI3 kinase inhibitor BKM120 with or without enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC). (2015) (12)
- Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide (2021) (12)
- High Dimensional Variable Selection with Error Control (2016) (12)
- A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. (2008) (11)
- Combined performance of screening and variable selection methods in ultra-high dimensional data in predicting time-to-event outcomes (2018) (11)
- LBA38Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) (2017) (11)
- Oncology clinical trials : successful design, conduct, and analysis (2010) (11)
- Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102 (2004) (11)
- A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials. (2004) (11)
- Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer (2019) (11)
- Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). (2012) (11)
- Comparison of futility monitoring guidelines using completed phase III oncology trials (2017) (11)
- Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer (2021) (11)
- Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. (2020) (10)
- Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer. (2020) (10)
- Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. (2020) (10)
- Characteristics of Attempted Suicide in the Middle East and North Africa Region: The Mediating Role of Arab Culture and Religion (2020) (10)
- Comorbidities predict overall survival (OS) in men with metastatic castrate-resistant prostate cancer (CRPC). (2011) (10)
- The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer (2007) (10)
- CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC). (2019) (10)
- Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series (2018) (10)
- The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. (2010) (10)
- A PHASE II STUDY OF DOCETAXEL, ESTRAMUSTINE, AND LOW DOSE HYDROCORTISONE IN HORMONE REFRACTORY PROSTATE CANCER: PRELIMINARY RESULTS OF CALGB 9780 (1999) (10)
- Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance) (2018) (9)
- Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. (2019) (9)
- Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP) (2016) (9)
- Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). (2010) (9)
- Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens. (2016) (9)
- Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans. (2008) (9)
- Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology (2015) 26(8) (1589–1604), (S0923753419318691), (10.1093/annonc/mdv257)) (2019) (9)
- Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102. (2004) (8)
- On model specification and selection of the Cox proportional hazards model (2013) (8)
- Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. (2020) (8)
- 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. (2004) (8)
- Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma (2021) (8)
- Residential metal contamination and potential health risks of exposure in adobe brick houses in Potosí, Bolivia. (2016) (8)
- Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC) (2019) (8)
- A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer (2022) (8)
- The Texas Breast Screening Project: Part I: Mammographic and Clinical Results (1993) (7)
- ASCO 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma: Guideline Summary. (2007) (7)
- Detection of low level benzene exposure in supermarket wrappers by urinary muconic acid (1999) (7)
- Serum Prostate Specific Antigen as a Predictor of Survival in Prostate Cancer Patients Treated with Second‐Line Hormonal Therapy (CALGB 9181) (2001) (7)
- Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC). (2018) (7)
- Making progress on progression in metastatic prostate cancer. (2015) (7)
- Are Patients With Elevated Liver Tests at Increased Risk of Drug-Induced Liver Injury? (2004) (7)
- Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. (2018) (7)
- A simple method for deriving the confidence regions for the penalized Cox’s model via the minimand perturbation (2017) (7)
- Risk Models for Individualized Prognosis in the Practice of Precision Oncology (2017) (7)
- Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial. (2018) (7)
- Oncology clinical trials (2013) (7)
- Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study. (2020) (7)
- Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer. (2019) (6)
- Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP) (2016) (6)
- Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (2018) (6)
- ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma. (2013) (6)
- Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). (2013) (6)
- Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial (2017) (6)
- Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). (2009) (6)
- Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT). (2021) (6)
- Evaluation of an Epithelial Plasticity (EP) Biomarker Panel in Men with Localized Prostate Cancer (2015) (6)
- PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer (2021) (6)
- Re : Carcinogenicity of the Drinking Water Mutagen 3-Chloro-4-( dichloromethyl )-5-hydroxy-2 ( 5 H )-furanone in the Rat (1997) (6)
- Flexible Frames and Control Sampling in Case-Control Studies (2008) (6)
- Combination of Radiotherapy and Short-Term Androgen Blockade with Abiraterone Acetate plus Prednisone for Men with High and Intermediate Risk Localized Prostate Cancer. (2020) (6)
- Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study. (2010) (6)
- Comparison of regression imputation methods of baseline covariates that predict survival outcomes (2020) (5)
- CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC). (2006) (5)
- A phase II study of estramustine (E), docetaxel (D) and exisulind in hormone-refractory prostate cancer (HRPC): Initial results of CALGB 90004 (2005) (5)
- Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study. (2021) (5)
- Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2012) (5)
- Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium (2023) (5)
- Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer (2022) (5)
- Textbook of Clinical Trials in Oncology (2019) (5)
- Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. (2021) (5)
- Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment (2009) (5)
- Reply to L. Dirix, B. De Laere et al, and A. Sharp et al. (2019) (5)
- A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC) (2007) (5)
- Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen (2005) (5)
- Estimand framework: Are we asking the right questions? A case study in the solid tumor setting (2020) (5)
- Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): Matching-adjusted indirect comparisons. (2020) (4)
- Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial. (2018) (4)
- Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC). (2013) (4)
- LBA-12 CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER (2019) (4)
- Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials (2022) (4)
- Efficacy of peripheral androgen blockade on prostate cancer: Results of CALGB 9782. (2004) (4)
- Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer. (2018) (4)
- Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide. (2020) (4)
- Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. (2019) (4)
- Analysis of Survival Data with Missing Measurements of a Time-Dependent Binary Covariate (2003) (4)
- On the use of min-max combination of biomarkers to maximize the partial area under the ROC curve. (2019) (4)
- Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary Endpoints. (2012) (4)
- Bevacizumab and everolimus in renal cancer: a rational way forward. (2010) (4)
- Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. (2018) (4)
- The impact of age on clinical outcomes in men with hormone refractory prostate cancer (2005) (4)
- A survey of clinical prediction tools in colorectal and lung cancers and melanoma. (2013) (4)
- What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (2022) (4)
- Activities and Accomplishments of the Cancer and Leukemia Group B Genitourinary Committee (2006) (3)
- Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. (2021) (3)
- Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer. (2008) (3)
- Management of Recurrent Prostate Cancer After Radiotherapy: Results From Calgb 9687, a Contemporary Prospective Multi-Institutional Salvage Radical Prostatectomy Series (2008) (3)
- Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non–Clear Cell Renal Cell Carcinoma (2021) (3)
- Attitudes and Knowledge Associated with being Undecided about Hormone Replacement Therapy: Results from a Community Sample (1999) (3)
- CALGB 90003: Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: An Intergroup Phase II Study. (2004) (3)
- Sample size selection in clinical trials when population means are subject to a partial order: one-sided ordered alternatives (2008) (3)
- Advancing Precision Oncology Through Biomarker-Driven Trials: Theory vs. Practice (2019) (3)
- Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480. (2004) (3)
- Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy. (2012) (3)
- Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes (2019) (3)
- Leukemia Group B Study Hormone-refractory Prostate Cancer Patients : A Cancer and Growth Factor Urine Levels as Predictors of Outcome in Vascular Endothelial Growth Factor and Basic Fibroblast (2001) (3)
- Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. (2022) (3)
- A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer (2022) (2)
- Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy. (2012) (2)
- Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of Outcome in Hormone-refractory Prostate Cancer Patients : A Cancer and Leukemia Group B Study 1 (2001) (2)
- Neglected craniocerebral gunshot wound resulting in an encephalocele: case report. (2000) (2)
- Score and deviance residuals based on the full likelihood approach in survival analysis (2020) (2)
- Disulfiram (DSF) pharmacokinetics (PK) and copper PET imaging in a phase Ib study of intravenous (IV) copper loading with oral DSF for patients with metastatic castration-resistant prostate cancer (mCRPC). (2020) (2)
- Progression‐free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint? (2015) (2)
- Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (2)
- Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. (2022) (2)
- Use of adrenal androgen levels to predict response to ketoconazole in patients with androgen independent prostate cancer: Results from CALGB 9583. (2004) (2)
- Title Identification of a Genomic Region between SLC 29 A 1 and HSP 90 AB 1 Associated with Risk of Bevacizumab-Induced Hypertension : CALGB 80405 ( Alliance ) (2018) (2)
- Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration‐resistant prostate cancer (2019) (2)
- Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782. (2006) (2)
- Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer. (2021) (2)
- Prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480. (2004) (2)
- In-depth Analysis of the 2019 Advanced Prostate Cancer Consensus Conference: The Importance of Representation of Medical Specialty and Geographic Regions (2021) (2)
- Statistical Considerations for Developing and Validating Prognostic Models of Clinical Outcomes (2018) (2)
- Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges (2022) (1)
- Decline in serum androgens and survival in metastatic castration resistant prostate cancer (MCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (alliance) (2018) (1)
- Abstract CT110: Olaparib (O) in patients (pts) with solid tumors with ATM mutation or deletion: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (2022) (1)
- Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel (2020) (1)
- Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. (2022) (1)
- Abstract CT135: Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reportedKRAS, NRAS, BRAFmutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (2019) (1)
- Social Construction of Arab Masculinity and Its Effects on Mental Health (2019) (1)
- Pan-Cancer Prognostic Models: Statistical Exercise or Clinical Tools? (2020) (1)
- Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. (2019) (1)
- Eligibility a nd R esponse G uidelines f or P hase I I C linical Trials i n A ndrogen-Indepen dent P rostate C ancer: Recommendations F rom t he P rostate-Specifi c A ntigen Working G roup (1999) (1)
- Abstract 646: Liquid biopsy transcriptomics identify pathways associated with poor outcomes and immune phenotypes in men with mCRPC (2022) (1)
- A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. (2013) (1)
- Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. (2023) (1)
- A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance). (2013) (1)
- AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY. (2020) (1)
- Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance). (2017) (1)
- Variable Selection Approaches in High-Dimensional Space (2021) (1)
- 978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study (2022) (1)
- 98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study (2022) (1)
- Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206. (2014) (1)
- p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study (2007) (1)
- An elevated body mass (BMI) index predicts for better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC). (2006) (1)
- Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223. (2018) (1)
- Five Year Results of Short Course Complete Androgen Blockade With Abiraterone Acetate and LHRH Agonist for Unfavorable Intermediate and Favorable High Risk Prostate Cancer. (2021) (1)
- Developing and Validating Prognostic Models of Clinical Outcomes (2019) (1)
- Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine (2021) (1)
- 1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC) (2022) (1)
- EFFECTS OF AGE, HEALTH-RELATED QUALITY OF LIFE, AND EDUCATION LEVEL ON MANAGEMENT AFTER BIOCHEMICAL FAILURE WITH WATCHFUL WAITING VERSUS HORMONAL THERAPY IN MEN WITH PROSTATE CANCER: RESULTS FROM THE COMPARE REGISTRY (2008) (1)
- Daily aspirin may reduce the risk of colorectal adenoma in people with a history of colorectal cancer (2003) (1)
- Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome (2015) (1)
- Reply to B. Rini et al and S. Buti et al. (2017) (1)
- Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial. (2016) (1)
- To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer-Weighing the Evidence. (2022) (1)
- Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). (2016) (1)
- Best (but oft-forgotten) practices: sample size and power calculation for a dietary intervention trial with episodically consumed foods. (2020) (1)
- MP44-01 A PROGNOSTIC MODEL FOR OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CARCINOMA: RESULTS FROM CALGB 90206 (ALLIANCE) (2015) (1)
- Androgens and Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel (2020) (1)
- Abstract CT146: Sunitinib (S) in patients (Pts) with metastatic colorectal cancer (mCRC) withFLT-3alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (2019) (0)
- The effect of race on progression-free survival in patients with metastatic hormone-refractory prostate cancer (HRPC): a pooled analysis of CALGB studies. (2004) (0)
- Estimation and testing of the relative risk of disease in case‐control studies with a set of k matched controls per case with known prevalence of disease (2012) (0)
- HIF-pathway genes prognostic for progression-free and overall survival in metastatic clear cell renal cell carcinoma (mccRCC). (2022) (0)
- Abstract CT231: Temsirolimus (T) in patients (pts) with solid tumors with PTEN mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (2023) (0)
- A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance). (2014) (0)
- 205: Variations in Prostate Cancer Care According to Race, Geographic Region, and Literacy: Initial Findings from the Compare Registry (2006) (0)
- Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance) (2016) (0)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (0)
- Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study (2023) (0)
- Null Results in Brief No Relationship between Ovarian Cancer Risk and Progesterone Receptor Gene Polymorphism in a Population-based, Case-Control Study in North Carolina 1 (2003) (0)
- Issue information (2013) (0)
- studies in developing countries . on education for use in health Measures of social class based (0)
- Contribution Use of Nonsteroidal Antiinflammatory Drugs and Distal Large Bowel Cancer in Whites and African Americans (2008) (0)
- Introduction to Clinical Trials (2019) (0)
- 1365P The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC) (2022) (0)
- Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer (2018) (0)
- External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
- Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS. (2022) (0)
- Quality of life outcomes for patients with metastatic castration‐resistant prostate cancer and pretreatment prognostic score (2023) (0)
- Interval Censoring (2019) (0)
- 207: Management of Prostate-specific Antigen (PSA) Recurrence after Initial Definitive Local Therapy for Prostate Cancer: Updated Results from the Compare Registry (2007) (0)
- External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. (2023) (0)
- Phase Ib trial of cabazitaxel and tasquinimod in men with heavily pretreated metastatic castration resistant prostate cancer (mCRPC): The CATCH trial. (2016) (0)
- Reply to F. Valcamonico et al. (2014) (0)
- Androgen R eceptor M utations i n A ndrogen-Indepen dent Prostate C ancer: C ancer a nd L eukemia G roup B S tudy 9 663 (2003) (0)
- The Changing Landscape of Clinical Research and Trials (2018) (0)
- PATIENT SATISFACTION WITH OBSERVATION OR HORMONAL THERAPY AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) AFTER BIOCHEMICAL FAILURE IN MEN WITH PROSTATE CANCER: RESULTS FROM THE COMPARE REGISTRY (2009) (0)
- 1596: Choices for Definitive Treatment of Early-Stage Prostate Cancer: Results from the Compare Registry (2006) (0)
- A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events (2015) (0)
- Regulatory genes in the Androgen Production, Uptake, and Conversion (APUC) pathway in advanced prostate cancer (2022) (0)
- Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC) (2019) (0)
- Improved Reporting in Abstracts When Uncertainty Is Inevitable. (2019) (0)
- Comparability of health-related quality of life (HRQOL), treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy (HT) versus observation (OBS): Results from the COMPARE registry. (2009) (0)
- Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401(ALLIANCE) (2014) (0)
- 795PA PROGNOSTIC MODEL FOR PREDICTING RADIOGRAPHIC PROGRESSION- FREE SURVIVAL (RPFS) IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER MEN TREATED WITH SECOND-LINE CHEMOTHERAPY. (2014) (0)
- A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy. (2013) (0)
- Receptor Gene and Risk of Ovarian Cancer Trinucleotide Repeat Polymorphisms in the Androgen (2007) (0)
- Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC). (2020) (0)
- Factorial Trials (2021) (0)
- Factor V l eiden Mutation and t hromboembolism r isk in Women r eceiving Adjuvant t amoxifen for Breast c ancer (2010) (0)
- Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC. (2022) (0)
- Sarcomatoid Renal Cell Carcinoma: An Immune Checkpoint-responsive Subset? (2021) (0)
- Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. (2021) (0)
- 501P A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19 (2022) (0)
- Predictive biomarkers of overall survival in patients with renal cell carcinoma treated with interferon alpha +/- bevacizumab: Results from CALGB 90206 (Alliance). (2021) (0)
- PD39-03 HYPOXIA-INDUCIBLE FACTOR (HIF) PATHWAY GENES PREDICT OVERALL SURVIVAL FOR METASTATIC CLEAR CELL RENAL CELL CARCINOMA (2020) (0)
- A min-max combination of biomarkers to improve diagnostic accuracy: A min-max combination of biomarkers to improve diagnostic accuracy (2011) (0)
- Hydrocortisone W ith o r W ithout M itoxantrone i n M en W ith Hormone-Refractory P rostate C ancer: R esults o f t he C ancer and L eukemia G roup B 9 182 S tudy (1999) (0)
- Erratum: Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemothery (Journal of the National Cancer Institute (2013) 105:7 (499-503)) (2014) (0)
- Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. (2023) (0)
- Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11] (2022) (0)
- A semiparametric modeling approach for analyzing clinical biomarkers restricted to limits of detection (2021) (0)
- Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2012) (0)
- Prognostic S ignificance o f R everse T ranscriptase P olymerase Chain R eaction f or P rostate-Specifi c A ntigen i n M etastatic Prostate C ancer: A N ested S tudy W ithin C ALGB 9 583 (2003) (0)
- Reply to M A Khattak et al. (2013) (0)
- Association of disease prognostic model (PM) with baseline quality of life (QOL) in metastatic castration resistant prostate cancer (mCRPC). (2019) (0)
- Prognostic M odel f or P redicting S urvival i n M en W ith Hormone-Refracto ry M etastatic P rostate C ancer (2003) (0)
- Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). (2023) (0)
- Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE). (2014) (0)
- Title: Liquid-biopsy transcriptomic profiling uncovers molecular mediators of resistance to androgen receptor signaling inhibition in lethal prostate cancer Authors: (2021) (0)
- Penalized weighted proportional hazards model for robust variable selection and outlier detection (2022) (0)
- Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma. (2022) (0)
- Continuous versus 6–8 chemotherapy courses with Epirubicin and Ifosfamide in advanced breast cancer (1993) (0)
- Authors' Disclosures of Potential Conflicts of Interest Theauthorsindicatednopotentialconflictsofinterest. (2011) (0)
- Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium. (2011) (0)
- Association between Family History Sensitivity in Upper Aerodigestive (1993) (0)
- Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC) (2019) (0)
- PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
- Tug of War During Traumatic Brain Injury (2020) (0)
- Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance). (2021) (0)
- LBA02-11 UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19) (2023) (0)
- Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. (2023) (0)
- Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B). (2018) (0)
- PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate resistant prostate cancer. (2023) (0)
- Race/ethnicity, literacy, and prostate cancer: Initial findings from the COMPARE registry. (2006) (0)
- Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes (2019) (0)
- Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial. (2016) (0)
- Impact of therapy on gene expression in high-risk prostate cancer (PCA) treated with neoadjuvant docetaxel and androgen deprivation therapy. (2016) (0)
- Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy. (2017) (0)
- Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC). (2020) (0)
- Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance). (2017) (0)
- On the design and the analysis of stratified biomarker trials in the presence of measurement error (2021) (0)
- Humanitarian Medicine and Moral Injury: An Inevitable Aftermath in Humanitarian Rebellion (2020) (0)
- PD27-09 MANAGEMENT OF RECURRENT PROSTATE CANCER AFTER RADIOTHERAPY: LONG-TERM RESULTS FROM CALGB 9687, A CONTEMPORARY PROSPECTIVE MULTI-INSTITUTIONAL SALVAGE PROSTATECTOMY SERIES (2014) (0)
- Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy. (2012) (0)
- Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC). (2016) (0)
- Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series (2018) (0)
- The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401). (2012) (0)
- Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma (2023) (0)
- Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs (2019) (0)
- Acne Vulgaris Burden, Risk Factors, Lifestyle Modification Influence and Treatment Options – A Review (2021) (0)
- Rare Presentation of Intracranial Hemorrhage post Guillain Barré Syndrome: A Case Report (2021) (0)
- Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. (2023) (0)
- Changes on endorectal MRI during neoadjuvant hormonal therapy for prostate cancer and biochemical outcome in men managed using radiation therapy: A prospective phase II Cancer and Leukemia Group B study (2007) (0)
- External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. (2012) (0)
- Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. (2023) (0)
- Liquid-biopsy transcriptomic profiling uncovers molecular mediators of resistance to androgen receptor signaling inhibition in lethal prostate cancer (2021) (0)
This paper list is powered by the following services:
Other Resources About Susan Halabi
What Schools Are Affiliated With Susan Halabi?
Susan Halabi is affiliated with the following schools:
